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the ACTs were the most dominant categories accounting for over 70% of market 
volume. SPs were the cheaper and most popular agents particularly in PMVs 
while the ACTs were the most prescribed agents dominant in retail pharmacies. 
Prices of the drugs ranged from $0.13 to $8.17 per adult oral dose. ACTs were the 
most expensive antimalarials with a median price of $5.23 ($1.83 - $8.17) in a 
country where over 50% of the population lives below $2 a day, making them 
unaffordable for majority of the low-income population. CONCLUSIONS: The  
use of ACTs has become very significant, but still below the required policy level 
as the drugs of choice in malaria treatment, limited by high prices and 
inadequate information. Results confirm that in many countries access to ACTs 
is hindered by unaffordable prices for majority of the population in addition to 
limited information on their relative efficiency in malaria treatment. 
Procurement is the most determinant of high cost, making it the key policy 
target for price reduction for improved affordability. Hence the expected impact 
of the AmFm will certainly boost access to the ACTs and would significantly 
change study findings  
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OBJECTIVES: To estimate the coverage of the Expanded Programme on 
Immunization among children ≤5 years old in Colombia, to evaluate the 
opportunity of vaccination, and to identify factors associated with low coverage. 
METHODS: We conducted a cross-sectional survey in 80 municipalities of 
Colombia, with census block groups as primary sampling units, and blocks as 
secondary units. We identified all children in the targeted age group living in the 
sampled blocks, and asked their caregivers to provide children´s immunization 
record cards, when available. We also collected basic socio-demographic 
information. All procedures adhered to international guidelines on ethical 
conduct of research, and were approved by the IRB at the National University of 
Colombia, School of Medicine. RESULTS: Estimated coverage was good for 
vaccines scheduled during the first 15 months of life: BCG 93.2% (95%CI: 92–94.4), 
DTP/Hib/HepB 89.6% (87.8–91.5), MMR 92.5% (90.8–94.2), yellow fever 89.5% (87.1–
91.8); but was lower among older children: DTP first booster dose 85.1% (83.4–
86.7), second booster dose 63.7% (57.3–70.2); MMR booster dose 52.9% (46.4–59.4). 
Opportunity of vaccination showed poorer results: for instance, timely 
administration of DTP/Hib/HepB occurred in only 44.2% of the children evaluated 
(41.4–47.1), and MMR in 71.2% (68.9–73.4). Higher socioeconomic status, time 
living in the municipality, mother´s years of school completed, and affiliation to 
social security were associated with better vaccine coverage (p<0.001); children 
of internally displaced families, children pertaining to a minority, and those 
coming from families with greater number of siblings had lower coverage. 
CONCLUSIONS: Vaccination coverage in children <15 months meets the WHO 
goal of 90%, or is very close to it, though coverage in older children falls below 
that goal. Delayed immunization is a common problem in Colombia, which may 
result in reduced protection. There are few modifiable factors associated with 
low coverage, though the identification of vulnerable populations may help to 
improve the reach of immunization programs.  
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OBJECTIVES: Investigate rational use of prescription drugs in Ministry of Health 
(MOH) in Saudi Arabia, using WHO level II indicators, and whether these 
measures are related to Pharmacy and Therapeutics Committee (P&TC) 
development level. METHODS: The study used retrospective data collected 
during 2003 from cross-sectional survey and prescriptions audit of 19 different 
outpatient settings of MOH hospitals in rural and urban areas; because of the 
scope of the study, we tested only 1 out of 12 indicators of WHO core drug use 
level II indicators (WHO/DAP/93.1); namely; the number of encounters with 
antibiotic prescribed. Binary logistic regression technique was used to test the 
likelihood of antibiotics prescribing across hospital and patient characteristics. 
RESULTS: Of 2850 patients, the average number of drugs prescribed per 
encounter was 2.41 higher than recommended target of WHO (<2); In hospitals 
serving urban areas, the antibiotics prescribing rates were 21.5% and 37.5% of 
total encounters in urban and rural hospitals respectively (WHO recommended 
target (<30%)). Antibiotics utilization was significantly higher in rural areas and 
in hospitals with undeveloped P&TC. The likelihood of antibiotics prescribing 
was 1.298 in hospitals with undeveloped P&TC compared to developed P&TC, 
2.550 for rural compared to urban areas, 1.390 for male patients, 4.462 for patient 
from (≤1)year, 5.412 for patients (2-4) years, 4.015 for patients (5-14)years, 1.439 
for patients (15-44)years. CONCLUSIONS: The data demonstrated that irrational 
use of medicines might exist in MOH hospitals, antibiotics overutilization in 
rural hospitals is an indication of it. The irrational prescribing might be 
associated with geographic areas, particularly, at hospitals serving rural areas. 
Furthermore, lack of effective P&TC might contribute to irrational prescribing in 
hospitals serving both urban and rural areas. Adoption of effective formulary 
system is recommended including adopting effective P&TC and strict guidelines 
and monitoring of antibiotic use to mitigate the risk of antibiotics resistance.  
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OBJECTIVES: The potential for neuropsychiatric side effects may be a treatment 
barrier for hepatitis C virus (HCV) patients with psychiatric comorbidities. This 
study’s primary objective was to compare medication treatment rates among 
HCV patients with and without psychiatric comorbidities. A secondary objective 
was assessing the impact of selection criteria on results. METHODS: Adult 
Medicaid beneficiaries with HCV (ICD-9-CM 070.44, 070.54) from July 1, 2009 
through June 30, 2011 and no interferon alfa (INF-a) treatment 6 months prior 
were identified using Truven Health MarketScan® Treatment Pathways. Patients 
without 6 months pre/post enrollment and a confirmatory HCV diagnosis were 
excluded. Post-index treatment rates given pre-index psychiatric comorbidity 
were calculated. Sensitivity analyses were performed, dropping the confirmatory 
diagnosis requirement and using a broader HCV diagnosis list (070.41, 070.44, 
070.51, 070.54, 070.7x). RESULTS: Psychiatric comorbidities measured in the 
sample (n=5,083) were alcohol abuse (16.6%), anxiety (20.3%), mood disorders 
(38.0%), schizophrenia (8.0%), and substance abuse (21.1%). Overall, 13.8% were 
treated with conventional or pegylated INF-a, most along with ribavirin. Protease 
inhibitor utilization (approved for HCV in 2011) was <1%. Alcohol abuse was 
associated with lower INF-a treatment rates (9.5% vs. 14.6%, p<0.001). Anxiety 
(15.9% vs. 13.2%, p=0.025) and mood disorder (15.1% vs. 13.0%, p=0.038) patients 
had higher rates, compared to patients without these comorbidities. Alcohol 
abuse and anxiety trends were similar after dropping the confirmatory diagnosis 
requirement (n= 10,335), but mood disorder was no longer significant. Using the 
broader diagnosis list (n=9,004), alcohol abuse (5.4% vs. 8.1%, p<0.001), 
schizophrenia (5.5% vs. 7.9%, p=0.017), and substance abuse (6.3% vs. 8.1%, 
p=0.009) were associated with lower treatment rates; anxiety and mood disorder 
had no significant effect. CONCLUSIONS: Psychiatric comorbidities were 
prevalent among HCV patients. Some comorbidities were associated with 
increased INF-a treatment rates, contrary to expectations. Minor sample 
selection changes impacted results, suggesting a need to carefully consider 
inclusion/exclusion criteria.  
 
PIN97  
COMORBID RISK AND CORRELATES OF PNEUMOCOCCAL VACCINATION 
AMONG LATENT CLASSES OF OLDER ADULTS IN THE CROSS-SECTIONAL 
NATIONAL HEALTH AND WELLNESS SURVEY IN BRAZIL  
Goren A1, Roberts CS2, Victor T3 
1Kantar Health, New York, NY, USA, 2Pfizer, New York, NY, USA, 3Kantar Health, Princeton, NJ, 
USA  
OBJECTIVES: To investigate predictors of pneumococcal polysaccharide vaccine 
(PPV) use across latent classes of older Brazilian adults, to understand 
characteristics associated with use in subpopulations with varying 
characteristics. METHODS: Data from the patient-reported, Internet-based 2011 
National Health and Wellness Survey in Brazil (n=12,000 adults) were used. 
Mixture modeling was applied to identify latent classes among respondents aged 
≥50 based on sociodemographics, health attitudes and behaviors, and health care 
resource use. Logistic regressions predicted PPV use (ever vs. never) within 
classes, from covariates including moderate-risk comorbidities (chronic disease, 
immunocompetent), high risk status (immunocompromised), flu vaccination in 
past year, and parent/caregiver of a child receiving pneumococcal vaccination. 
RESULTS: Among 3,195 respondents ≥50, two latent classes emerged. Class 1 
(assigned n=1,981) versus 2 (n=1,214) respondents had higher adjusted odds of 
being educated beyond high school (OR=26.75), partnered (OR=2.29), insured 
(OR=2.08), male (OR=1.80), exercising (OR=1.09), overweight/obese (OR≥1.18), and 
wealthier (OR≥1.81), all p<0.001; they were also younger (Mean=56.2 vs. 72.5 
years, respectively), visited traditional providers and the emergency room more 
frequently, and had higher physician-contact and lower prescription-avoidant 
attitudes, all p<0.05. Class 1 (9.9%) versus 2 (6.9%) PPV use was higher, as were 
rates of heart and lung disease, smoking, and child vaccination, while flu 
vaccination was lower, all p<0.05. In Class 1, child pneumococcal vaccination 
(OR=6.82), flu vaccination (OR=2.49), and chronic heart disease (OR=1.60) 
predicted PPV use, all p≤0.015. In Class 2, only child vaccination (OR=5.61) was 
significant, p=0.029. CONCLUSIONS: In Brazil, child vaccination may be a 
population-wide predictor of adult PPV uptake. Among younger, more affluent 
respondents with better health care access and attitudes, higher PPV use was 
associated with flu vaccination and heart disease. Among remaining elderly 
respondents, PPV uptake was lower and not significantly associated with risk 
factors, suggesting the need for better risk-based access.  
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OBJECTIVES: Improving and reducing disparities in time to HAART initiation and 
virologic suppression (VS) can assist in reducing U.S. human immunodeficiency 
virus (HIV) incidence. METHODS: Using data from ARV-naïve patients who 
enrolled in HOPS in 2000-2010 ≤6 months of HIV diagnosis and attended ≥2 visits, 
we assessed temporal trends and correlates of initiating HAART and achieving 
VS (<500 copies/mL) via Kaplan-Meier curves and Cox proportional hazards 
models. RESULTS: Among 1,112 patients included in our analysis, patients were 
less likely to start HAART and achieve VS ≤1 year of diagnosis if they were 
